Search results
Results from the WOW.Com Content Network
An ELISA technique for CMV-specific IgM is available, but may give false-positive results unless steps are taken to remove rheumatoid factor or most of the IgG antibody before the serum sample is tested. Because CMV-specific IgM may be produced in low levels in reactivated CMV infection, its presence is not always indicative of primary infection.
IgG antibodies are smaller and require assistance to bridge well enough to form a visual agglutination reaction. Reagents used to enhance IgG detection are referred to as potentiators. RBCs have a net negative charge called zeta potential which causes them to have a natural repulsion for one another.
Screening for cytomegalovirus is not mandatory in all jurisdictions, and positive donors may still donate at sperm banks. [3]Donor screening for cytomegalovirus (CMV) is carried out by testing for IgG antibodies against CMV that are produced if the donor ever has contracted CMV, which is the case in between 50% and 80% of adults. [4]
CMV colitis may be clinically manifested with diarrhea (usually non-bloody), abdominal pain, weight loss and anorexia. The diagnosis of CMV colitis is based on serology, CMV antigen testing and colonoscopy with biopsy. Clinical suspicion should be aroused in the setting of immunocompromised patient but it is much rarer in immunocompetent patient.
Cytomegalovirus (CMV) (from cyto-'cell' via Greek κύτος kútos - 'container' + μέγας mégas 'big, megalo-' + -virus via Latin vīrus 'poison') is a genus of viruses in the order Herpesvirales, in the family Herpesviridae, [3] in the subfamily Betaherpesvirinae. Humans and other primates serve as natural hosts.
Congenital CMV cannot be diagnosed if the infant is tested more than one week after birth. [citation needed] Visually healthy infants are not routinely tested for CMV infection although only 10–20% will show signs of infection at birth [citation needed] though up to 80% may go onto show signs of prenatal infection in later life. If a pregnant ...
Anti-sense oligonucleotide: Anti-sense FDA-licensed in 1998; Withdrawn in EU (2002), US (2006) Fosamprenavir: HIV ViiV Healthcare: Amprenavir pro-drug: 2003 (FDA), 2004 Foscarnet: Herpes: Pyrophosphate analogue DNA polymerase inhibitor: 1991 Ganciclovir (Cytovene) [9] Cytomegalovirus (CMV) [10] Competitive nucleoside analogue dGTP inhibitor ...
This antiinfective drug article is a stub. You can help Wikipedia by expanding it.